AI Agentic Workflow for Synthetic Rare Disease Patient Cohort Augmentation

This core agent orchestrates conditional generative models (e.g., GANs, diffusion models) to create synthetic patient records that match specific, rare disease phenotypes and biomarker profiles. It ingests real-world data (RWD) schemas and prevalence statistics, then enforces clinical plausibility constraints during generation to ensure outputs reflect realistic comorbidities, lab value ranges, and disease progression patterns. The agent is parameterized via a researcher portal, allowing on-demand cohort specification.

A system of specialized validation agents runs in parallel to gate cohort release. Statistical Fidelity Agents perform automated tests (KS, propensity score, multivariate distribution) against source RWD. Clinical Logic Agents check for implausible clinical events (e.g., incompatible diagnoses). Privacy Assurance Agents simulate re-identification attacks and compute differential privacy metrics, ensuring outputs meet k-anonymity and HIPAA Safe Harbor standards before provisioning.

This orchestration layer (built with LangGraph or similar) manages the end-to-end workflow and integrates with enterprise systems. It handles IAM-authenticated data requests from researchers, applies appropriate data use agreement constraints, triggers the generation and validation pipeline, and upon approval, delivers synthetic cohorts to secure sandboxes or directly into research platforms like OMOP CDMs, Electronic Data Capture (EDC) systems, or AI training environments. It also enforces retention policies and maintains full lineage.

For studies requiring temporal understanding, this component generates synthetic patient lifelines. Using agent-based simulation and graph models of disease pathways, it creates timestamped sequences of clinical events—diagnoses, treatments, lab results, and outcomes—that reflect the natural history of a rare disease and its interactions with common comorbidities. This is critical for counterfactual analysis, trial simulation, and training predictive models where dynamics are key.

This agent automates the complex data engineering required to make synthetic outputs usable. It analyzes the target system's schema (e.g., an EHR like Epic, a clinical data warehouse, or a Medidata Rave EDC), maps the generated synthetic data fields, performs necessary terminological coding (e.g., to SNOMED CT or ICD-10), and formats the output for seamless ingestion. This eliminates the manual transformation bottleneck, allowing synthetic data to plug directly into existing analytical pipelines.

A continuous monitoring system tracks the operational and financial performance of the synthetic data pipeline. It logs metrics on generation latency, compute cost, statistical drift from source data, and validation failure rates. Using this telemetry, it can trigger automated responses—such as retraining generative models, scaling cloud resources, or alerting data engineers—to ensure the workflow delivers reliable, cost-effective, and high-fidelity cohorts at scale.

Primary Goal: Accelerate target validation and trial design for rare disease programs where patient recruitment is the primary bottleneck. Key Role: Defines the clinical plausibility rules, target patient phenotypes, and outcome variables the synthetic cohort must replicate. Validates that generated data supports meaningful statistical power for intended analyses. Implementation Touchpoint: Provides real-world data (RWD) samples and protocol logic; gates release of synthetic cohorts based on fidelity validation against known disease progression patterns.

Primary Goal: Build and maintain the conditional generative model pipeline (e.g., GANs, diffusion models) and multi-agent validation system that produces statistically robust synthetic records. Key Role: Architects the data ingestion, feature engineering, model training, and automated fidelity scoring layers. Implements orchestration (e.g., LangGraph) to manage the workflow from raw RWD to validated synthetic dataset. Implementation Touchpoint: Integrates with EHR/OMOP data lakes, manages GPU training clusters, and deploys the generation API for on-demand cohort creation.

Primary Goal: Ensure synthetic data generation meets HIPAA Safe Harbor/Expert Determination standards and internal data governance policies, creating a defensible privacy shield. Key Role: Defines the differential privacy (ε) budget, re-identification risk thresholds, and data use agreements. Approves the automated de-identification and risk-testing workflow before any synthetic data is shared. Implementation Touchpoint: Reviews audit logs from the governance agent; signs off on synthetic data packages for external partnership sharing.

Primary Goal: Provide the secure, scalable infrastructure and integrations that make the synthetic data pipeline a reliable enterprise service. Key Role: Provisions the secure research environment (e.g., AWS/GCP VPC), manages access controls via IAM, and builds connectors to downstream systems (e.g., EDC like Medidata Rave, analytics platforms like Databricks). Implementation Touchpoint: Implements the data provisioning API and manages the SLA for pipeline uptime and generation latency.

Primary Goal: Quantify the ROI of synthetic data in reducing cycle times and de-risking rare disease R&D investments. Key Role: Prioritizes use cases (e.g., control arm generation vs. biomarker discovery), secures funding for the workflow build, and tracks metrics like cost-per-synthetic-patient and time-to-actionable-dataset. Implementation Touchpoint: Manages the phased rollout from pilot (one disease area) to scale (enterprise platform), ensuring the workflow delivers measurable value against program milestones.

Primary Goal: Use synthetic cohorts to accelerate feasibility assessments, protocol refinement, and site selection without lengthy legal data transfer agreements. Key Role: Consumer of the synthetic data via a secure portal; provides feedback on dataset utility for specific trial design tasks. Their early engagement validates the workflow's business impact. Implementation Touchpoint: Accesses synthetic data sandboxes for simulation; uses synthetic proxies to align on study assumptions before committing real budget or patient data.